Recent News

• 06.11.2025 - uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
• 06.02.2025 - uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
• 05.29.2025 - uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
• 05.09.2025 - uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
• 05.05.2025 - uniQure to Announce First Quarter 2025 Financial Results
• 04.17.2025 - uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

Recent Filings

• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.09.2025 - 8-K Current report
• 05.09.2025 - EX-99.1 EX-99.1
• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2025 - DEF 14A Other definitive proxy statements